01—Abstract
Summary
Summary of the 8-K filed March 5, 2026. Cited figures are marked; the original filing is the authoritative source.
Moderna, Inc. has entered into a significant settlement agreement with Arbutus Biopharma Corporation and Genevant Sciences GmbH to resolve all ongoing patent infringement litigation.
This agreement, effective March 3, 2026, provides crucial certainty for Moderna's infectious disease product portfolio, including its key vaccines Spikevax® and mRESVIA®, as well as its future pipeline, by eliminating future royalty obligations. The settlement includes an initial noncontingent payment of $950 milliona to Arbutus/Genevant, due by July 8, 2026. Furthermore, the agreement outlines a potential additional contingent payment of up to $1.3 billion, which is tied to the outcome of Moderna's appeal to the Court of Appeals for the Federal Circuit.
This appeal concerns whether Section 1498 of U.S. Code limits Arbutus/Genevant's claims for infringement on vaccine doses sold to the U.S. Government. If Moderna prevails in its appeal on all relevant doses, this contingent payment will not be due.
Conversely, a partial win or an unfavorable ruling could result in a prorated contingent payment. The settlement also grants Moderna a fully paid-up, royalty-free, irrevocable license to utilize lipid SM-102-based lipid nanoparticle (LNP) formulations in its infectious disease vaccines.
02—Key points
Key Highlights
- Moderna settles all global patent litigation with Arbutus/Genevant regarding its infectious disease portfolio.
- An initial noncontingent payment of $950 million is due to Arbutus/Genevant by July 8, 2026.
- A potential additional contingent payment of up to $1.3 billion hinges on the outcome of Moderna's Section 1498 appeal.
- The settlement resolves future royalty obligations for Moderna's existing and pipeline infectious disease vaccines.
- Moderna secures a royalty-free, irrevocable license for its LNP formulation technology used in key vaccines.
- The resolution provides significant clarity and certainty for Moderna's future product development and commercialization.
- Moderna retains the right to appeal a specific aspect of the District Court's decision related to government contract sales.
03—Questions
Frequently Asked Questions
What is the total potential financial exposure for Moderna under this settlement?
Moderna will make an initial noncontingent payment of $950 million. There is a potential additional contingent payment of up to $1.3 billion, which is dependent on the outcome of Moderna's appeal regarding Section 1498. Therefore, the maximum potential payout is $2.25 billion, but this is subject to the appeal.
What is the significance of Moderna's appeal to the Federal Circuit?
Moderna is appealing the District Court's decision on whether Section 1498 of U.S. Code bars Arbutus/Genevant's claims for direct and indirect infringement on vaccine doses sold to the U.S. Government under a specific contract. If Moderna wins this appeal, the contingent payment will not be due, significantly reducing the overall cost of the settlement.
Does this settlement affect Moderna's ability to sell its existing vaccines or develop new ones?
No, this settlement is designed to resolve patent disputes and provides certainty for Moderna's infectious disease portfolio, including Spikevax® and mRESVIA®, and its future vaccine pipeline. It also includes a royalty-free license for the specific LNP formulation, ensuring continued development and sales without future royalty obligations related to this dispute.
When will the initial payment be made?
The initial noncontingent lump sum payment of $950 million is to be made on or before July 8, 2026.
04—Continue